Clinical Trial Search

Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34

Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale

Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472

Primary: Uric Acid Level — 8.23; 8.03 mg/dL

Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants

Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale

Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants

Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356

Primary: Measurement of Tophi by MRI - Difference in Volument Between Visits — -0.05 centimeters³ (cm³) — p=0.785

Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants

Primary: Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS — -26.1…

Primary: ATP Levels in Synovial Fluid — 4.4; 31.4 nanomoles/ml

Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale

Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001

Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants

Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 71.0; 38.5 percentage of participants — p=< 0.0001

Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants

Primary: Average Percent Difference in Area Between Visits — 29 mm²

Primary: Preference IVR vs RheumPRO — 3; 28 Participants

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale — 100; 100 Percentage of participants

Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…

Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants

Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001

Primary: Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6 — 78.6 percentage of participants

Primary: Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours — -1.40; -1.55; -0.69…

Primary: Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit. — 56; 76; 94; 0 percentage of subjects — p=<0.001

Primary: Percent Changes of Serum Uric Acid Levels From Baseline Levels — -30.93; -49.91; -54.32; -2.05 Percent change — p=<0.0001

Primary: Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups — 17.1; 32 Millimeters

Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 9.1 percentage of participants